Humacyte Inc (HUMA)
6.33
-0.09
(-1.40%)
USD |
NASDAQ |
May 17, 16:00
6.35
+0.02
(+0.32%)
After-Hours: 16:55
Humacyte Total Liabilities (Quarterly): 135.31M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 135.31M |
| December 31, 2023 | 114.68M |
| September 30, 2023 | 112.39M |
| June 30, 2023 | 106.99M |
| March 31, 2023 | 101.09M |
| December 31, 2022 | 87.37M |
| Date | Value |
|---|---|
| September 30, 2022 | 107.55M |
| June 30, 2022 | 104.10M |
| March 31, 2022 | 160.58M |
| December 31, 2021 | 164.36M |
| September 30, 2021 | 227.50M |
| December 31, 2020 | 457.00M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
87.37M
Minimum
Dec 2022
457.00M
Maximum
Dec 2020
156.58M
Average
113.53M
Median
Total Liabilities (Quarterly) Benchmarks
| Adial Pharmaceuticals Inc | 0.6531M |
| Gritstone Bio Inc | 123.25M |
| Precision BioSciences Inc | 147.54M |
| Puma Biotechnology Inc | 163.17M |
| Revance Therapeutics Inc | 606.79M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 161.47M |
| Shareholders Equity (Quarterly) | 26.15M |